Abstract
Immunotherapy Checkpoint blockade immunotherapy has shown considerable promise for the control of metastatic melanoma. Despite the success stories, there are still many patients who do not respond at all. Thus, identification of molecular markers to predict which patients could have beneficial treatment outcomes is key. Krieg et al. used high-dimensional single-cell mass cytometry to analyze the peripheral blood of melanoma patients. Samples were analyzed before and after the patients' 12-week course of treatment with PD-1 immunotherapy. Those patients who responded better had increased activation and frequency of monocytes (defined as CD14+CD16−HLA-DRhi cells) in their blood before starting treatment. The researchers propose that monocyte profiling could be used to stratify patients before commencing PD-1 immunotherapy. Nat. Med. 10.1038/nm.4466 (2018).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
